No Chemo; Rituximab Alone for Indolent Lymphoma? No Chemo; Rituximab Alone for Indolent Lymphoma?

New results showing a 10-year overall survival rate of 73% with rituximab alone suggest that patients can skip chemotherapy. But this may not be appropriate for all patients, suggests an expert.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news